Last Friday, the Medicines and Healthcare Products Regulatory Agency approved Merck & Co Inc’s (NYSE:MRK) Winrevair (sotatercept) for adult patients with pulmonary arterial hypertension (PAH).

Merck booked just under $600 million last year in alliance revenues from the pair, but its attention is now moving to new therapies including sotatercept, a TGF-beta-targeting PAH drug Merck ...

In a deal that could top $1 billion, Merck & Co has teamed up with US biotech Janux Therapeutics to bring T-cell immunotherapies to cancer patients. The agreement sees San Diego-based Janux in ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Welcome to Fierce Pharma's regulatory tracker for the first half of 2025. On this page, we're recording the regulatory progress of in-market products, including expansions into key geographies and ...

Derived prices are not provided by exchanges. They are derived by market makers in CFD OTC market and hence prices may not be accurate and may differ from the actual market price, meaning prices ...

When you buy through our links, Business Insider may earn an affiliate commission. Learn more T-shirts are quintessential for any wardrobe, especially during the spring and summer. They're a ...

Long-sleeved T-shirts are an underrated wardrobe staple. As stylist and fashion designer Jordan Page of @veryadvanced points out, the humble long-sleeved tee can look “classier than short ...

After hours: January 3 at 7:59:30 p.m. EST ...